Imagion Biosystems today announced that the U.S. Patent and Trademark Office has issued patent #10194825 B2 for “Methods and Apparatuses for the localization and treatment of disease such as cancer.”
The new patent is a continuation-in-part of the company’s core patent which applies to the use of magnetic nanoparticles for the detection of diseases such as cancer.
“This is an important addition to our intellectual property portfolio,” said Bob Proulx, Executive Chairman. “We have long held the view that using our targeted magnetic nanoparticles for detection cancer was only the first step. There is a much broader opportunity to combine detection with treatment.”
View the entire announcement here.
This news was lodged with the Australian Securities Exchange.
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited